NCT02503657View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 9, 2016

Primary Completion Date

December 7, 2020

Study Completion Date

March 15, 2022

Conditions
Idiopathic Pulmonary FibrosisIPF
Interventions
DRUG

MN-001

A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity

DRUG

Matching Placebo

Excipients of MN-001/tipelukast

Trial Locations (1)

17033

Penn State University College of Medicine, Milton S. Hershey Medical Center, Hershey

Sponsors

Lead Sponsor

MediciNova
All Listed Sponsors
lead

MediciNova

INDUSTRY